InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. It is developing Neuro-Spinal Scaffold implant, an investigational bioresorbable polymer scaffold for implantation at the site of injury within a spinal cord. InVivo Therapeutics Holdings Corp. has research collaboration with the Q Therapeutics, Inc. for the evaluation of the combination of PLGA-PLL based Neuro-Spinal Scaffold with adult neural progenitor cells, including those from induced pluripotent stem cells. The company was founded in 2005 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NVIV
Previous Symbol
CUSIPN/A
Phone617-863-5500
Debt
Debt-to-Equity RatioN/A
Current Ratio6.94
Quick Ratio6.94
Price-To-Earnings
Trailing P/E Ratio-0.10
Forward P/E Ratio-0.16
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$7.37 per share
Price / Book0.25
Profitability
EPS (Most Recent Fiscal Year)($18.50)
Net Income$-26,740,000.00
Net MarginsN/A
Return on Equity-292.02%
Return on Assets-140.72%
Miscellaneous
Employees12
Outstanding Shares9,310,000
Market Cap$18.24 million
OptionableNot Optionable
Invivo Therapeutics (NASDAQ:NVIV) Frequently Asked Questions
What is Invivo Therapeutics' stock symbol?
Invivo Therapeutics trades on the NASDAQ under the ticker symbol "NVIV."
When did Invivo Therapeutics' stock split? How did Invivo Therapeutics' stock split work?
Invivo Therapeutics shares reverse split on the morning of Tuesday, April 17th 2018. The 1-25 reverse split was announced on Monday, April 9th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Monday, April 16th 2018. An investor that had 100 shares of Invivo Therapeutics stock prior to the reverse split would have 4 shares after the split.
How were Invivo Therapeutics' earnings last quarter?
Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) released its quarterly earnings results on Thursday, November, 8th. The biotechnology company reported ($0.42) earnings per share (EPS) for the quarter. View Invivo Therapeutics' Earnings History.
When is Invivo Therapeutics' next earnings date?
Has Invivo Therapeutics been receiving favorable news coverage?
Press coverage about NVIV stock has trended somewhat positive this week, according to InfoTrie Sentiment. The research firm rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Invivo Therapeutics earned a news impact score of 1.2 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the stock's share price in the near term.
Who are some of Invivo Therapeutics' key competitors?
Some companies that are related to Invivo Therapeutics include Endologix (ELGX), Invo Bioscience (IVOB), iCAD (ICAD), Pro-Dex (PDEX), Repro-Med Systems (REPR), Motus GI (MOTS), CAS Medical Systems (CASM), SANUWAVE Health (SNWV), Spectral Medical (EDTXF), Restoration Robotics (HAIR), Nephros (NEPH), Obalon Therapeutics (OBLN), AIT Therapeutics (AITB), Lianluo Smart (LLIT) and Interpace Diagnostics Group (IDXG).
Who are Invivo Therapeutics' key executives?
Invivo Therapeutics' management team includes the folowing people:
- Dr. Richard M. Toselli, Pres, CEO, Chief Medical Officer & Director (Age 61)
- Dr. Robert S. Langer Jr., Co-Founder and Member of Scientific Advisory Board (Age 69)
- Dr. Joseph Philip Vacanti, Co-Founder (Age 69)
- Mr. Jeffrey Modestino, Principal Financial Officer, Principal Accounting Officer & Treasurer
- Mr. William D'Agostino PE, Sr. VP of Operations
Who are Invivo Therapeutics' major shareholders?
Invivo Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (3.05%), Vanguard Group Inc (0.92%), Vanguard Group Inc. (0.92%) and IMS Capital Management (0.34%). View Institutional Ownership Trends for Invivo Therapeutics.
Which institutional investors are buying Invivo Therapeutics stock?
How do I buy shares of Invivo Therapeutics?
Shares of NVIV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Invivo Therapeutics' stock price today?
One share of NVIV stock can currently be purchased for approximately $1.86.
How big of a company is Invivo Therapeutics?
Invivo Therapeutics has a market capitalization of $18.24 million. The biotechnology company earns $-26,740,000.00 in net income (profit) each year or ($18.50) on an earnings per share basis. Invivo Therapeutics employs 12 workers across the globe.
What is Invivo Therapeutics' official website?
How can I contact Invivo Therapeutics?
Invivo Therapeutics' mailing address is ONE KENDALL SQUARE SUITE B14402, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-863-5500 or via email at [email protected]
MarketBeat Community Rating for Invivo Therapeutics (NASDAQ NVIV)
MarketBeat's community ratings are surveys of what our community members think about Invivo Therapeutics and other stocks. Vote "Outperform" if you believe NVIV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVIV will underperform the S&P 500 over the long term. You may vote once every thirty days.
